Images

Filter by

Figure 6 Gene Ontology Enrichment
Figure 6: Gene Ontology Enrichment
Figure 5 Tissue Enrichment of Dilated Cardiomyopathy associated Immune Genes
Figure 5: Tissue Enrichment of Dilated Cardiomyopathy-associated Immune Genes
Figure 4 Tissue level Expression of Dilated Cardiomyopathy linked Genes
Figure 4: Tissue-level Expression of Dilated Cardiomyopathy-linked Genes
Figure 3 Sensitivity Analysis of CD4 Treg T cells and Dilated Cardiomyopathy
Figure 3: Sensitivity Analysis of CD4+ Treg T-cells and Dilated Cardiomyopathy
Figure 2 Immune Cell Associations with Dilated Cardiomyopathy and Congestive Heart Failure
Figure 2: Immune Cell Associations with Dilated Cardiomyopathy and Congestive Heart Failure
Figure 1 Overview of Study Framework and Instrument VARIABLE Selection Workflow
Figure 1: Overview of Study Framework and Instrument VARIABLE Selection Workflow
Figure 4 Timeline of Clinical Events from Admission Through Discharge
Figure 4: Timeline of Clinical Events from Admission Through Discharge
Figure 3 Transoesophageal Echocardiography Reconstruction of the Iatrogenic Atrial Septal Defect after Closure with an Amplatzer Occluder
Figure 3: Transoesophageal Echocardiography Reconstruction of the Iatrogenic Atrial Septal Defect after Closure with an Amplatzer Occluder
Figure 2 Transoesophageal Echocardiography Reconstruction of the Iatrogenic Atrial Septal Defect Prior to Closure
Figure 2: Transoesophageal Echocardiography Reconstruction of the Iatrogenic Atrial Septal Defect Prior to Closure
Figure 1 2D Transoesophageal Echocardiography View of the Iatrogenic Atrial Septal Defect
Figure 1: 2D Transoesophageal Echocardiography View of the Iatrogenic Atrial Septal Defect
Table 1 Glucagon like Peptide 1 Receptor Agonists in Heart Failure Key Relevant Trials
Table 1: Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Key Relevant Trials
Figure 1 Cardiovascular Benefits of Glucagon like Peptide 1 Receptor Agonists
Figure 1: Cardiovascular Benefits of Glucagon-like Peptide-1 Receptor Agonists